BioCentury
ARTICLE | Clinical News

Tazemetostat: Phase II started

January 25, 2016 8:00 AM UTC

Epizyme began an open-label, international Phase II trial to evaluate 800 mg oral tazemetostat twice daily in about 90 adult patients. The first cohort will comprise patients with malignant rhabdoid t...